About: MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, and glioblastoma, as well as prevention of acute respiratory distress syndrome. The company is also developing MN-001 (tipelukast), an orally bioavailable small molecule compound in Phase 2 clinical trial to treat fibrotic and other metabolic disorders, including nonalcoholic fatty liver disease and hypertriglycedemia. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.
Sector: Healthcare
Industry: Biotechnology
Latest price: $1.40 (-4.76%)
MNOV NASDAQ MediciNova Inc
MediciNova Inc share price
Atividade de preço de MNOV
Último preço
$ 1,400
Variação (24h)
-0,07 USD (4,76%)
Volume
53K
Volume (média 4 sem.)
-
Abertura
$ 1,46
Variação do dia
$ 1,39 - $ 1,50
Fechamento anterior
$ 1,47
Último negócio
29 Oct, 8:00 pm GMT+0
Atrasado
29 Oct, 8:00 pm GMT+0
MNOV price performance
Atrasado
29 Oct, 8:00 pm GMT+0
quote.marketSignals